Understanding Sickle cell disease: Causes, symptoms, and treatment options

被引:40
作者
Elendu, Chukwuka [1 ]
Amaechi, Dependable C. [2 ]
Alakwe-Ojimba, Chisom E. [3 ]
Elendu, Tochi C. [4 ]
Elendu, Rhoda C. [5 ]
Ayabazu, Chiagozie P. [6 ]
Aina, Titilayo O. [6 ]
Aborisade, Ooreofe [7 ]
Adenikinju, Joseph S. [8 ]
机构
[1] Fed Univ Teaching Hosp, Owerri, Nigeria
[2] Igbined Univ Okada, Okada, Nigeria
[3] Chukwuemeka Odumegwu Ojukwu Univ, Anambra State, Nigeria
[4] Imo State Univ, Owerri, Nigeria
[5] Van Horbachevsky Ternopil Natl Med Univ, Ternopol, Ukraine
[6] Babcock Univ, Ogun State, Nigeria
[7] Olabisi Onabanjo Univ Teaching Hosp, Shagamu, Nigeria
[8] Northwick Pk Hosp London Northwest NHS Trust, London, England
关键词
acute chest syndrome; disease-modifying therapies; hematopoietic stem cell transplantation; Sickle cell disease; stroke; vaso-occlusive crisis; ACUTE CHEST SYNDROME; ANEMIA; HEMOGLOBIN; TRANSPLANTATION; EPIDEMIOLOGY; PATHOGENESIS; TRANSFUSIONS; HYDROXYUREA; HEMOLYSIS; CHILDREN;
D O I
10.1097/MD.0000000000035237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sickle cell disease (SCD) is a hereditary blood disorder characterized by the production of abnormal hemoglobin molecules that cause red blood cells to take on a crescent or sickle shape. This condition affects millions of people worldwide, particularly those of African, Mediterranean, Middle Eastern, and South Asian descent. This paper aims to provide an overview of SCD by exploring its causes, symptoms, and available treatment options. The primary cause of SCD is a mutation in the gene responsible for producing hemoglobin, the protein that carries oxygen in red blood cells. This mutation has abnormal hemoglobin called hemoglobin S, which causes red blood cells to become stiff and sticky, leading to various health complications. Patients with SCD may experience recurrent pain, fatigue, anemia, and increased infection susceptibility. Treatment options for SCD focus on managing symptoms and preventing complications. This includes pain management with analgesics, hydration, and blood transfusions to improve oxygen delivery. Hydroxyurea, a medication that increases the production of fetal hemoglobin, is commonly used to reduce the frequency and severity of pain crises. Additionally, bone marrow or stem cell transplants can cure select individuals with severe SCD. Finally, understanding the causes, symptoms, and treatment options for SCD is crucial for healthcare professionals, patients, and their families. It enables early diagnosis, effective symptom management, and improved quality of life for individuals with this chronic condition.
引用
收藏
页数:7
相关论文
共 43 条
[11]   The number of people with sickle-cell disease in the United States: National and state estimates [J].
Brousseau, David C. ;
Panepinto, Julie A. ;
Nimmer, Mark ;
Hoffmann, Raymond G. .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (01) :77-78
[12]   Mechanisms of disease - Pathogenesis and treatment of sickle cell disease [J].
Bunn, HF .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :762-769
[13]   EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA [J].
CHARACHE, S ;
TERRIN, ML ;
MOORE, RD ;
DOVER, GJ ;
BARTON, FB ;
ECKERT, SV ;
MCMAHON, RP ;
BONDS, DR ;
ORRINGER, E ;
JONES, S ;
STRAYHORN, D ;
ROSSE, W ;
PHILLIPS, G ;
PEACE, D ;
JOHNSONTELFAIR, A ;
MILNER, P ;
KUTLAR, A ;
TRACY, A ;
BALLAS, SK ;
ALLEN, GE ;
MOSHANG, J ;
SCOTT, B ;
STEINBERG, M ;
ANDERSON, A ;
SABAHI, V ;
PEGELOW, C ;
TEMPLE, D ;
CASE, E ;
HARRELL, R ;
CHILDERIE, S ;
EMBURY, S ;
SCHMIDT, B ;
DAVIES, D ;
KOSHY, M ;
TALISCHYZAHED, N ;
DORN, L ;
PENDARVIS, G ;
MCGEE, M ;
TELFER, M ;
DAVIS, A ;
CASTRO, O ;
FINKE, H ;
PERLIN, E ;
SITEMAN, J ;
GASCON, P ;
DIPAOLO, P ;
GARGIULO, S ;
ECKMAN, J ;
BAILEY, JH ;
PLATT, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1317-1322
[14]   High Prevalence of Sickle Cell Trait in African Americans with ESRD [J].
Derebail, Vimal K. ;
Nachman, Patrick H. ;
Key, Nigel S. ;
Ansede, Heather ;
Falk, Ronald J. ;
Kshirsagar, Abhijit V. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (03) :413-417
[15]  
El-Hazmi Mohsen A F, 2011, Indian J Med Res, V134, P597, DOI 10.4103/0971-5916.90984
[16]  
Embury SH., 1995, Clin Appl Thromb Hemost, V1, P85
[17]  
Ezekekwu Chinedu A, 2018, J Trop Dis Public Health, V6, P259, DOI 10.4172/2329-891X.1000259
[18]   Pulmonary Complications of Sickle Cell Disease. [J].
Gladwin, Mark T. ;
Vichinsky, Elliott .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) :2254-2265
[19]   Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study [J].
Hankins, JS ;
Ware, RE ;
Rogers, ZR ;
Wynn, LW ;
Lane, PA ;
Scott, JP ;
Wang, WC .
BLOOD, 2005, 106 (07) :2269-2275
[20]   Population Estimates of Sickle Cell Disease in the US [J].
Hassell, Kathryn L. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (04) :S512-S521